Search Results for "Mirrx Therapeutics"

08:15 EDT 29th August 2014 | BioPortfolio

Original Source: Mirrx Therapeutics

Mirrx Therapeutics is developing a novel microRNA-blocking technology, Blockmirs, which are antisense oligonucleotides that bind to a microRNA binding site on an mRNA. This unique approach blocks single microRNA:mRNA interactions, resulting in extremely targeted regulation of specific mRNAs, thereby potentially reducing unintended effects on gene activity.

Matching Channels


Matching News

Wounds - Pipeline Review, H1 2014

Recently added to the BioPortfolio report store, Wounds - Pipeline Review, H1 2014 is a new report from Global Markets Direct published on 2014-04-27. This 255-page report is available in PDF from $2...

Matching PubMed Articles


Search Whole site using Google

Search BioPortfolio:
Advertisement Advertisement